Sign In
Buy DRUG
$73.26
-1.37 (-1.84%)
At Close: Jul 31, 2026
Vistagen Appoints Douglas J. Williamson to its Board of Directors
08:30am, Friday, 31'st Jul 2026
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to dev
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
10:56am, Thursday, 23'rd Jul 2026
The consensus price target hints at a 107.5% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward tren
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
01:02pm, Wednesday, 22'nd Jul 2026
Bright Minds Biosciences Inc. (DRUG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
07:18pm, Tuesday, 26'th May 2026
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selecti
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
05:31pm, Thursday, 21'st May 2026
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of “Moderate Buy” from Brokerages
04:24am, Saturday, 28'th Mar 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the firm, MarketBeat.com reports. One a
Bright Minds Biosciences to Present at Upcoming Conferences
04:30pm, Wednesday, 25'th Feb 2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly select
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of “Moderate Buy” from Analysts
01:50am, Monday, 12'th Jan 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight research firms that are covering the stock, Marketbeat reports. One
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
11:56am, Friday, 09'th Jan 2026
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
09:33pm, Wednesday, 07'th Jan 2026
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced public
Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating
03:00pm, Wednesday, 07'th Jan 2026
Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resistant epilepsies. DRUG's BMB-101 achieved -73.1% and -63.3% median seizure reductions in Absence Epi
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
04:00pm, Tuesday, 06'th Jan 2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the launch of a public offering of common share
New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday
11:52am, Tuesday, 06'th Jan 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) stock is trading higher on Tuesday after the company shared topline results from its Phase 2 BREAKTHROUGH trial of BMB-101 for drug-resistant Absence Seizu
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on develo
Bright Mind Biosciences shares surge on positive epilepsy drug trial results
06:12am, Tuesday, 06'th Jan 2026
Shares of Bright Minds Biosciences Inc (NASDAQ: DRUG, CSE:DRUG) jumped almost 25% after the company announced positive topline results from its Phase 2...
